Skip to search boxSkip to navigationSkip to main content

Hypertension and incident cardiovascular events following ibrutinib initiation

  • Tyler Dickerson
    ,
  • Tracy Wiczer
    ,
  • Allyson Waller
    ,
  • Jennifer Philippon
    ,
  • Kyle Porter
    ,
  • Devin Haddad
Scholary Output:
Contribution to journal
Article
 Peer-review

Abstract

Ibrutinib is associated with dramatic efficacy against B-cell malignancies. Yet, it has been linked with potentially limiting cardiotoxicity, including emerging reports of profound hypertension (HTN). The long-term incidence, severity, and impact of HTN development with ibrutinib are unknown. Therefore, in 562 consecutive patients treated with ibrutinib for B-cell malignancies from 2009 through 2016, we assessed the new/incident or worsened HTN (systolic blood pressure [BP] cutoff, 130 mm Hg). Observed incident HTN rates were compared with Framingham-heart–predicted incident HTN rates. We also evaluated the relationship of HTN to the development of other major adverse cardiovascular events (MACEs), including arrhythmia, myocardial infarction, stroke, heart failure, and cardiovascular death. Further, we assessed the effects of different antihypertensive classes on ibrutinib-related HTN. Overall, 78.3% of ibrutinib users developed new or worsened HTN over a median of 30 months. New HTN developed in 71.6% of ibrutinib users, with a time to 50% cumulative incidence of 4.2 months. Among those without preceding HTN, 17.7% developed high-grade HTN (BP >160/100 mm Hg). In multivariate regression, new or worsened HTN was associated with increased MACEs (hazard ratio [HR], 2.17; 95% confidence interval [CI], 1.08-4.38). No single antihypertensive class was associated with prevention or control of ibrutinib-related HTN. However, antihypertensive initiation was associated with a lower risk of a MACE (HR, 0.40; 95% CI, 0.24-0.66). Collectively, these data suggest that ibrutinib is associated with a substantial increase in the incidence and severity of HTN, and that HTN development carries a higher risk of subsequent cardiotoxic events.

Publication Information

Output type

Scholary Output:
Contribution to journal
Article
 Peer-review

Original language

English (US)

Pages from-to (Number of pages)

Pages 1919-1928 (10 pages)

Journal (Volume, Issue Number)

Blood (Volume 134, Issue 22)

Publication milestones

  • Published - 2019

Publication status

Published - 2019

ISSN

0006-4971

Publication IDs

  • PubMed: 31582362
  • Scopus: 85075812906
  • ORCID: /0000-0003-0253-1174/work/110363102

Access to documents

Publication metrics

Metrics

Fractional count
1
Fractional count
0.08
Fractional count
12
Fractional count
0.92
Fractional count
1
Fractional count
1
Scopus
citations
240, opens in new tab

PlumX, opens in new tab

Mentions
5
Captures
176
Citation count
241